Compugen (CGEN) to Release Quarterly Earnings on Tuesday

Compugen (NASDAQ:CGEN) is scheduled to be releasing its earnings data before the market opens on Tuesday, November 12th. Analysts expect Compugen to post earnings of $0.21 per share for the quarter. Persons interested in listening to the company’s earnings conference call can do so using this link.

Compugen Stock Down 1.7 %

Shares of Compugen stock opened at $1.78 on Friday. The firm has a market capitalization of $158.85 million, a P/E ratio of -17.80 and a beta of 2.64. Compugen has a 52 week low of $0.53 and a 52 week high of $3.03. The firm’s 50 day moving average is $1.79 and its two-hundred day moving average is $1.88.

Analyst Upgrades and Downgrades

Separately, StockNews.com raised Compugen from a “hold” rating to a “buy” rating in a report on Thursday, August 15th.

About Compugen

Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company’s immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I monotherapy clinical study in patients with advanced malignancies through sequential dose escalations; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase II clinical study in patients with advanced or metastatic non-small cell lung cancer.